Company Filing History:
Years Active: 1996-2002
Title: Etienne DePlaen: Innovator in Cancer Research
Introduction
Etienne DePlaen is a prominent inventor based in Brussels, Belgium. He has made significant contributions to the field of cancer research, particularly in the area of immunotherapy. With a total of 9 patents to his name, his work focuses on the interaction between peptides and HLA-Cw*16 molecules, which has important implications for cancer treatment.
Latest Patents
DePlaen's latest patents include groundbreaking inventions such as "Isolated molecules which complex with HLA-Cw*16 molecules, and uses thereof." This invention involves the identification of peptides that bind to HLA-Cw*16 molecules, potentially provoking lysis of the cells to which they attach by cytolytic T cells. Additionally, he has developed "Isolated peptides which comply with HLA-CW16 molecules and uses," which also describes diagnostic and therapeutic applications related to these peptides.
Career Highlights
Etienne DePlaen is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research. His work has been instrumental in understanding how specific peptides can be utilized in cancer therapies, paving the way for innovative treatment options.
Collaborations
Throughout his career, DePlaen has collaborated with notable colleagues such as Thierry R Boon-Falleur and Pierre Van Der Bruggen. These partnerships have enhanced the scope and impact of his research in the field of cancer immunology.
Conclusion
Etienne DePlaen's contributions to cancer research through his innovative patents and collaborations highlight his role as a key figure in the scientific community. His work continues to inspire advancements in therapeutic strategies for cancer treatment.